Glaxo asks Brazil’s health regulator for emergency use of Sotrovimab Covid-19 drug

RIO DE JANEIRO, BRAZIL – The National Health Regulatory Agency (Anvisa) received, on Monday (19), a request for emergency use of the drug Sotrovimab, a monoclonal antibody developed for the treatment of Covid-19. The request was submitted by the laboratory Glaxo Smith Kline.

The deadline for analyzing the request is 30 days, counting from the confirmation that all the necessary documents have been delivered. According to Anvisa, the drug has not had clinical studies conducted in Brazil so far.

UAE FINDS DRUG IS 100% SUCCESSFUL AT PREVENTING DEATHS

Between 30 June and 13 July, 6,175 patients in the UAE (United Arab Emirates) received Sotrovimab. The drug was 100% successful in preventing deaths and 99% effective in stopping admissions to intensive care, UAE authorities said. Close to 97% of recipients fully recovered within 14 days, which was in line with previous findings.

The results were announced on Saturday (17) by the Ministry of Health and Prevention, in collaboration with Abu Dhabi’s Department of Health and Dubai Health Authority. The UAE was one of the first countries in the world to receive Sotrovimab.

The MoHAP has approved the use of Sotrovimab, produced by global biopharmaceutical company GlaxoSmithKline (GSK). It has also been approved for emergency use by the US Food and Drug Administration.

About 52% of patients were aged 50 or above and almost all recipients had comorbidities such as obesity, cancer, cardiovascular disease, or diabetes.

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error